Fig. 2.
Treatment of cancer cell lines with 5-Aza -2′-Deoxycytidine enhances CTL killing, which correlates with upregulation of PRAME target antigen. a Expression of PRAME mRNA as determined by q-RT-PCR following treatment of indicated cell lines with 3 μM DAC for 72 h. b, c and d Specific killing by PRA100−108-specific CTL clones 10D (b and d) and CTL Line 7 (c) of indicated cell lines pretreated with 3 μM DAC for 72 h. In some experiments, the indicated blocking monoclonal antibodies were added to the chromium assay where A2 indicates HLA-A0201 blocking antibody and ISO is isotype control. In all panels, error bars denote SEM of triplicate estimates of a single experiment. All chromium assays were performed over 4 h